Immediate Impact

64 standout
Sub-graph 1 of 22

Citing Papers

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Oesophageal cancer
2024 Standout
4 intermediate papers

Works of Francesca Pucci being referenced

CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)
2018
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
2003

Author Peers

Author Last Decade Papers Cites
Francesca Pucci 239 119 96 25 317
Wen‐Yih Liang 200 79 151 17 350
Lauren M. Postlewait 279 96 106 18 342
Laura Antolino 138 155 171 31 318
Lauren M. Postlewait 263 77 104 38 304
Tetsufumi Kojima 107 106 176 22 318
Richard Knoop 136 53 77 26 295
Katsumi Kurihara 176 117 192 19 338
J-P. Metges 201 195 160 20 304
Silvana Leo 248 87 68 17 354
Carrie Luu 167 86 94 32 283

All Works

Loading papers...

Rankless by CCL
2026